The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.
 
Martijn P. Lolkema
Consulting or Advisory Role - Incyte; Johnson & Johnson; Novartis; Sanofi
Research Funding - Astellas Pharma (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Merck Sharp & Dohme
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Clovis Oncology; Cybrexa Therapeutics; Ellipses Pharma; Karus Therapeutics; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Filip Yves Francine Leon De Vos
Research Funding - Abbvie (Inst); BioClin Therapeutics (Inst); Novartis (Inst)
Expert Testimony - Bristol-Myers Squibb
 
Martin David Forster
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Novartis; PharmaMar; Roche
Research Funding - AstraZeneca; Boehringer Ingelheim; Merck; MSD
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck; MSD; Roche
 
ERIC ANGEVIN
Consulting or Advisory Role - Celgene; GlaxoSmithKline; MedImmune; Merck Sharp & Dohme
Research Funding - Abbvie; GlaxoSmithKline; MedImmune; Octimet; Pfizer; Sanofi
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Innate Pharma
 
Marion Libouban
Employment - Octimet
 
Ellen Jansen
Employment - Galapagos NV; Octimet
 
Marc Tjwa
Employment - Octimet
 
Eric Ciamporcero
Employment - Johnson & Johnson; Octimet
 
Ann Meulemans
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
 
Annegret Van der Aa
Employment - Galapagos NV; Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Galapagos NV
 
Timothy Pietro Suren Perera
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
Consulting or Advisory Role - Octimet
Research Funding - Octimet
Patents, Royalties, Other Intellectual Property - Patent Holder
 
Glen Clack
Employment - Carrick Therapeutics; Octimet
Stock and Other Ownership Interests - Carrick Therapeutics; Octimet
Consulting or Advisory Role - Aptus Clinical; Inventiva Pharma; MorEx; Octimet; PCI Biotech; Redx Pharma
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Janssen; Octimet; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BerGenBio
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro